MicroRNAs and polycystic kidney disease

17Citations
Citations of this article
17Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Polycystic kidney disease (PKD), the most common genetic cause of chronic renal failure, is characterized by the presence of numerous fluid-filled cysts in renal parenchyma. Despite recent progress, no FDA-approved therapy is available to retard cyst growth. Here, we review current evidence implicating two groups of microRNAs (miRNAs) - the miR-17∼92 cluster and miR-200s - in the pathogenesis of PKD. We present a new hypothesis for cyst growth involving miRNAs and regulation of PKD gene dosage. We propose that manipulating miRNA function in an attempt to normalize PKD gene dosage represents a novel therapeutic strategy in PKD. © 2012 Elsevier Ltd. All rights reserved.

Cite

CITATION STYLE

APA

Noureddine, L., Hajarnis, S., & Patel, V. (2013). MicroRNAs and polycystic kidney disease. Drug Discovery Today: Disease Models. Elsevier Ltd. https://doi.org/10.1016/j.ddmod.2013.10.001

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free